Vanguard Group Inc. Increases Holdings in DexCom, Inc. $DXCM

Vanguard Group Inc. lifted its holdings in DexCom, Inc. (NASDAQ:DXCM) by 1.8% in the second quarter, Holdings Channel reports. The fund owned 48,322,405 shares of the medical device company’s stock after purchasing an additional 866,506 shares during the quarter. Vanguard Group Inc. owned approximately 0.12% of DexCom worth $4,218,063,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in DXCM. Andra AP fonden bought a new stake in shares of DexCom in the 2nd quarter valued at approximately $26,000. Zions Bancorporation National Association UT bought a new position in shares of DexCom during the 1st quarter valued at approximately $27,000. Anderson Financial Strategies LLC purchased a new stake in DexCom during the 1st quarter valued at $37,000. Migdal Insurance & Financial Holdings Ltd. bought a new stake in DexCom in the second quarter worth $45,000. Finally, Atlantic Union Bankshares Corp purchased a new position in DexCom during the second quarter worth $70,000. 97.75% of the stock is owned by institutional investors.

Insider Buying and Selling

In other DexCom news, Director Bridgette P. Heller sold 1,012 shares of the company’s stock in a transaction on Wednesday, November 12th. The stock was sold at an average price of $58.07, for a total value of $58,766.84. Following the completion of the sale, the director directly owned 27,031 shares in the company, valued at approximately $1,569,690.17. This represents a 3.61% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Jacob Steven Leach purchased 18,200 shares of the company’s stock in a transaction dated Monday, November 10th. The shares were purchased at an average cost of $55.04 per share, for a total transaction of $1,001,728.00. Following the transaction, the chief operating officer directly owned 331,697 shares in the company, valued at approximately $18,256,602.88. This represents a 5.81% increase in their position. The SEC filing for this purchase provides additional information. Insiders have sold 9,999 shares of company stock valued at $619,391 over the last 90 days. 0.32% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

DXCM has been the topic of a number of analyst reports. Weiss Ratings cut shares of DexCom from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Tuesday. Morgan Stanley cut their price target on shares of DexCom from $89.00 to $63.00 and set an “equal weight” rating on the stock in a report on Monday, November 10th. William Blair raised shares of DexCom to a “strong-buy” rating in a research note on Thursday, July 31st. Wall Street Zen lowered DexCom from a “strong-buy” rating to a “buy” rating in a research report on Sunday. Finally, BTIG Research reduced their price target on DexCom from $109.00 to $85.00 and set a “buy” rating on the stock in a report on Friday, October 31st. Three investment analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $87.62.

DexCom Trading Down 0.7%

Shares of DXCM opened at $59.73 on Thursday. The firm has a market capitalization of $23.30 billion, a price-to-earnings ratio of 41.48, a PEG ratio of 1.43 and a beta of 1.40. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.52 and a quick ratio of 1.35. DexCom, Inc. has a 1-year low of $54.11 and a 1-year high of $93.25. The company has a 50-day moving average of $66.17 and a 200 day moving average of $76.90.

DexCom (NASDAQ:DXCM) last issued its earnings results on Thursday, October 30th. The medical device company reported $0.61 EPS for the quarter, topping analysts’ consensus estimates of $0.57 by $0.04. The business had revenue of $1.21 billion for the quarter, compared to the consensus estimate of $1.18 billion. DexCom had a net margin of 13.29% and a return on equity of 30.41%. During the same period in the prior year, the firm earned $0.45 EPS. The company’s revenue for the quarter was up 21.6% compared to the same quarter last year. DexCom has set its FY 2025 guidance at EPS. On average, research analysts expect that DexCom, Inc. will post 2.03 EPS for the current year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.